Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6573575 | 0.82 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL6571934 | 0.74 | SCN9A (0.46) | P2RX7SCN9AHSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7689118 | 0.73 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL6571558 | 0.72 | P2RX7 (0.65) | P2RX7 | |
| SCHEMBL6571918 | 0.71 | P2RX7 (0.64) | P2RX7 | |
| Hydrochloric Acid SCHEMBL6571536 | 0.70 | P2RX7 (0.63) | P2RX7 | |
| SCHEMBL6572535 | 0.69 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL7568675 | 0.66 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL6574199 | 0.66 | P2RX7 (0.65) | P2RX7 | |
| Hydrochloric Acid SCHEMBL6572764 | 0.66 | P2RX7 (0.64) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720452-B2 | SUBSTITUTED BENZMIDE-N-METHYL ADMANATANE DERIVATIVES USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ASTRAZENECA AB (SE) | 2004-04-13 | — | — | US | disclosed |
| EP-1240132-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20020193414-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193414-A1 | Adamantane derivatives | APP, ADORA1, ADAM17 | P2RX7 894/4885SCN9A 562/4885HSD11B1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.